Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

PURPOSE: PROSTVAC, a viral vector–based immunotherapy, prolonged median overall survival (OS) by 8.5 months versus placebo in metastatic castration-resistant prostate cancer in a phase II study. This phase III study further investigated those findings. PATIENTS AND METHODS: Patients were randomly as...

Descripción completa

Detalles Bibliográficos
Autores principales: Gulley, James L., Borre, Michael, Vogelzang, Nicholas J., Ng, Siobhan, Agarwal, Neeraj, Parker, Chris C., Pook, David W., Rathenborg, Per, Flaig, Thomas W., Carles, Joan, Saad, Fred, Shore, Neal D., Chen, Liddy, Heery, Christopher R., Gerritsen, Winald R., Priou, Frank, Langkilde, Niels C., Novikov, Andrey, Kantoff, Philip W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
RAPID COMMUNICATION
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494360/
https://www.ncbi.nlm.nih.gov/pubmed/30817251
http://dx.doi.org/10.1200/JCO.18.02031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494360/
https://www.ncbi.nlm.nih.gov/pubmed/30817251
http://dx.doi.org/10.1200/JCO.18.02031

Ejemplares similares